Bayer to present results from AMD trials

(CercleFinance.com) - Bayer will present new analyses from the pivotal PULSAR and PHOTON trials of Eylea 8 mg (aflibercept 8 mg) at the annual meeting of the European Society of Retina Specialists, to be held in Barcelona, Spain, from September 19 to 22, 2024.


A new indirect comparison between aflibercept 8 mg and faricimab assesses the timing and extent of disease activity, applying similar disease activity criteria in the respective pivotal phase 3 neovascular (wet) age-related macular degeneration (AMD) trials.

Three new analyses will highlight the rapid and sustained two-year fluid control and consistent safety profile of Eylea 8 mg in AMD patients.

' Many of our patients need a sustained approach to controlling their retinal disease while preserving their vision. This is exactly what the clinical trials with Eylea 8 mg have shown, and it represents a turning point in retinal care', said Professor Anat Loewenstein, Director of the Department of Ophthalmology at Tel Aviv Medical Center, Israel.

Copyright (c) 2024 CercleFinance.com. All rights reserved.